British journal of pharmacology · 2025
Critical role of the mast cell/tryptase/PAR2 axis in anastrozole-induced pain.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fialho Maria Fernanda Pessano, Tonello Raquel, Brum Evelyne Silva, Becker Gabriela, Bunnett Nigel W, Oliveira Sara Marchesan
Аннотация
BACKGROUND AND PURPOSE: Anastrozole, an aromatase inhibitor, is used to treat postmenopausal women with hormone receptor-positive breast cancer, but also induces musculoskeletal pain and can lead to therapeutic regimen suspension. Aromatase inhibitors promote the release of pro-inflammatory substances from sensitised nerve fibres, which might lead to peripheral mast cell activation.
EXPERIMENTAL APPROACH: We explore if tryptase released by peripheral mast cells could activate the protease-activated receptor 2 (PAR2) to sustain anastrozole-induced painful symptoms.
KEY RESULTS: Anastrozole caused mechanical allodynia, muscle strength loss, and increased mast cell number and tryptase levels in the plantar tissue of male C57BL/6 mice. Depletion (using compound 48/80) or stabilisation (using ketotifen fumarate) of mast cells prevented anastrozole-induced mechanical allodynia and muscle strength loss. Compound 48/80 also prevented the increase in the number of mast cells in the plantar tissue. Tryptase inhibitors nafamostat and gabexate, or PAR2 inhibitors ENMD-1068 and AZ3451, reduced the anastrozole-induced mechanical allodynia and muscle strength loss. Furthermore, anastrozole did not cause mechanical allodynia and muscle strength loss in global (PAR2-/-) or sensory neuron-specific (PAR2 Nav 1.8-/-) PAR2 knockout mice. Local sub-nociceptive doses of the PAR2 agonists (tryptase, trypsin or 2F) enhanced the anastrozole-induced mechanical sensitivity in wild-type mice, which was reduced by pre-treatment with AZ3451. PAR2-/- or PAR2 Nav 1.8-/- mice treated with anastrozole did not respond to local sub-nociceptive doses of PAR2 agonists.
CONCLUSIONS AND IMPLICATIONS: Our results provide a new mechanism underlying anastrozole-induced pain, highlighting the mast cell/tryptase/PAR2 axis as a therapeutic target to manage painful symptoms.
EXPERIMENTAL APPROACH: We explore if tryptase released by peripheral mast cells could activate the protease-activated receptor 2 (PAR2) to sustain anastrozole-induced painful symptoms.
KEY RESULTS: Anastrozole caused mechanical allodynia, muscle strength loss, and increased mast cell number and tryptase levels in the plantar tissue of male C57BL/6 mice. Depletion (using compound 48/80) or stabilisation (using ketotifen fumarate) of mast cells prevented anastrozole-induced mechanical allodynia and muscle strength loss. Compound 48/80 also prevented the increase in the number of mast cells in the plantar tissue. Tryptase inhibitors nafamostat and gabexate, or PAR2 inhibitors ENMD-1068 and AZ3451, reduced the anastrozole-induced mechanical allodynia and muscle strength loss. Furthermore, anastrozole did not cause mechanical allodynia and muscle strength loss in global (PAR2-/-) or sensory neuron-specific (PAR2 Nav 1.8-/-) PAR2 knockout mice. Local sub-nociceptive doses of the PAR2 agonists (tryptase, trypsin or 2F) enhanced the anastrozole-induced mechanical sensitivity in wild-type mice, which was reduced by pre-treatment with AZ3451. PAR2-/- or PAR2 Nav 1.8-/- mice treated with anastrozole did not respond to local sub-nociceptive doses of PAR2 agonists.
CONCLUSIONS AND IMPLICATIONS: Our results provide a new mechanism underlying anastrozole-induced pain, highlighting the mast cell/tryptase/PAR2 axis as a therapeutic target to manage painful symptoms.